690 — Uni-Bio Science Income Statement
0.000.00%
- HK$668.78m
- HK$614.07m
- HK$552.98m
- 59
- 61
- 59
- 66
Annual income statement for Uni-Bio Science, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 209 | 353 | 440 | 485 | 553 |
Cost of Revenue | |||||
Gross Profit | 181 | 277 | 335 | 393 | 461 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 280 | 373 | 397 | 408 | 461 |
Operating Profit | -70.9 | -19.5 | 43.7 | 76.7 | 92.4 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -70.9 | -20 | 43.3 | 75.9 | 91.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -71.3 | -19.6 | 38.5 | 70.9 | 82.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -71.3 | -19.6 | 38.5 | 70.9 | 82.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -71.3 | -19.6 | 38.5 | 70.9 | 82.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.007 | -0.001 | 0.006 | 0.011 | 0.014 |
Dividends per Share |